Angiogenesis as a target in neuroblastoma

Abstract Several research investigations on neuroblastoma (NB) have shown the important dependency of this embryonic tumour on angiogenesis, especially in the advanced and aggressive stages. However, the first pre-clinical data on anti-angiogenic drugs in NB have not been published until recently an...

Full description

Saved in:
Bibliographic Details
Published in:European journal of cancer (1990) 2008-08, Vol.44 (12), p.1645-1656
Main Authors: Rössler, Jochen, Taylor, Melissa, Geoerger, Birgit, Farace, Francoise, Lagodny, Jeanette, Peschka-Süss, Regine, Niemeyer, Charlotte M, Vassal, Gilles
Format: Article
Language:English
Subjects:
Angiogenesis
Angiogenesis Inhibitors - therapeutic use
Anti-angiogenesis
Bevacizumab
Biological and medical sciences
Hematology, Oncology and Palliative Medicine
Humans
Hypoxia - metabolism
Medical sciences
Microcirculation
Neoplasm Staging
Neovascularization, Pathologic - drug therapy
Neovascularization, Pathologic - etiology
Neovascularization, Pathologic - genetics
Neuroblastoma
Neuroblastoma - blood supply
Neuroblastoma - drug therapy
Neuroblastoma - genetics
Oncogenes - genetics
Pharmacology. Drug treatments
Schwann Cells - metabolism
Tumors
VEGF
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Several research investigations on neuroblastoma (NB) have shown the important dependency of this embryonic tumour on angiogenesis, especially in the advanced and aggressive stages. However, the first pre-clinical data on anti-angiogenic drugs in NB have not been published until recently and clinical trials with anti-angiogenic agents in NB treatment protocols are still missing. Here, we summarise current knowledge on the important role and mechanisms of angiogenesis in NB, and report available pre-clinical results of anti-angiogenic agents used to treat NB. This review clearly shows that angiogenesis is a target in NB and that clinical trials are urgently needed to bring forward promising anti-angiogenesis treatment strategies into NB therapy.
ISSN:0959-8049
1879-0852
DOI:10.1016/j.ejca.2008.05.015